Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older

References

• Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/. (accessed 3 Jan 2022.
   Google Scholar
• Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49(1):49–56.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Hallek M, Goede V. Management of unfit elderly patients with chronic lymphocytic leukemia. Eur J Intern Med. 2018;58:7–13.
   PubMed Web of Science ®Google Scholar
• Stauder R, Eichhorst B, Hamaker ME, et al. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international society of geriatric oncology (SIOG) task force. Ann Oncol. 2017;28(2):218–227.
   PubMed Web of Science ®Google Scholar
• Liu MA, DuMontier C, Murillo A, et al. Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies. Blood. 2019;134(4):374–382.
   PubMed Web of Science ®Google Scholar
• Rotbain EC, Niemann CU, Rostgaard K, et al. Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death. Leukemia. 2021;35(9):2570–2580.
   PubMed Web of Science ®Google Scholar
• Goede V, Cramer P, Busch R, on behalf of the German CLL Study Group, et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica. 2014;99(6):1095–1100.
   PubMed Web of Science ®Google Scholar
• Goede V, Bahlo J, Chataline V, et al. Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. Leuk Lymphoma. 2016;57(4):789–796.
   PubMed Web of Science ®Google Scholar
• Al‐Sawaf O, Bahlo J, Robrecht S, et al. Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. Br J Haematol. 2018;183(5):727–735.
   PubMed Web of Science ®Google Scholar
• Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Hillmen P, O’Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133(19):2031–2042.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528.
   PubMed Web of Science ®Google Scholar
• Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120.
   PubMed Web of Science ®Google Scholar
• Huber H, Edenhofer S, von Tresckow J, et al. Phase 2 study of obinutuzumab (GA-101), ibrutinib and venetoclax (CLL2-GIVe) in patients with untreated high-risk chronic lymphocytic leukemia. Blood. 2022;139(9):1318–1329.
   PubMed Web of Science ®Google Scholar
• Cramer P, von Tresckow J, Robrecht S, et al. Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial. Haematologica. 2021;106:543–554.
   PubMed Web of Science ®Google Scholar
• von Tresckow J, Cramer P, Bahlo J, et al. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2019;33(5):1161–1172.
   PubMed Web of Science ®Google Scholar
• Cramer P, von Tresckow J, Bahlo J, et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(9):1215–1228.
   PubMed Web of Science ®Google Scholar
• Cramer P, Von Tresckow J, Fink A-M, et al. Bendamustine followed by obinutuzumab and idelalisib in patients with chronic lymphocytic leukemia (CLL): CLL2-BCG trial of the german CLL study group (GCLLSG). Blood. 2020;136(Supplement 1):21–23.
   Google Scholar
• Statistisches Bundesamt Deutschland – GENESIS-Online: Statistik: 12621. https://www-genesis.destatis.de/genesis/online?operation=previous&levelindex=1&step=1&titel=Ergebnis&levelid=1645614702262&acceptscookies=false#abreadcrumb. (accessed 23 Feb 2022.
   Google Scholar
• Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437.
   PubMed Web of Science ®Google Scholar
• Sharman JP, Banerji V, Fogliatto LM, et al. ELEVATE TN: Phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone Vs O plus chlorambucil (clb) in patients (pts) with treatment-naive chronic lymphocytic leukemia (CLL). Blood. 2019;134(Supplement_1):31–31.
   Google Scholar
• Gordon MJ, Churnetski M, Alqahtani H, et al. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer. 2018;124(15):3192–3200.
   PubMed Web of Science ®Google Scholar
• An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a Meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779–790.
   Web of Science ®Google Scholar
• Tedeschi A, Frustaci AM, Mauro FR, et al. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib? Blood Adv. 2021;5(24):5490–5500.
   PubMed Web of Science ®Google Scholar
• Michallet A-S, Campidelli A, Lequeu H, et al. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: a real-world experience of 71 patients treated in France: a study from the French Innovative Leukemia Organization (FILO) group. Am J Hematol. 2017;92(6):E105–E107.
   PubMed Web of Science ®Google Scholar
• Eyre TA, Roeker LE, Fox CP, et al. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. Br J Haematol. 2020;188(6):918–923.
   PubMed Web of Science ®Google Scholar
• Reda G, Mattiello V, Frustaci AM, et al. Ibrutinib in over-eighties patients with chronic lymphocytic leukemia: a multicenter italian cohort. HemaSphere. 2022;6:557–558.
   Google Scholar
• Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679–1705.
   PubMed Web of Science ®Google Scholar
• Fresa A, Autore F, Galli E, et al. Treatment options for elderly/unfit patients with chronic lymphocytic leukemia in the era of targeted drugs: a comprehensive review. JCM. 2021;10(21):5104.
   Google Scholar
• Aprahamian I, Cezar NO de C, Izbicki R, et al. Screening for frailty with the FRAIL scale: a comparison with the phenotype criteria. J Am Med Dir Assoc. 2017;18(7):592–596.
   PubMed Web of Science ®Google Scholar
• Wildiers H, Heeren P, Puts M, et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–2603.
   PubMed Web of Science ®Google Scholar
• Goede V, Neuendorff NR, Schulz RJ, et al. Frailty assessment in the care of older people with haematological malignancies. Lancet Heal Longev. 2021;2(11):e736–e745.
   PubMedGoogle Scholar
• Hanlon P, Nicholl BI, Jani BD, et al. Frailty and pre-frailty in Middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK biobank participants. Lancet Public Heal. 2018;3(7):e323–e332.
   PubMed Web of Science ®Google Scholar